



HAL
open science

Improvement of zinc intestinal absorption and reduction of zinc/iron interaction using metal bound to the caseinophosphopeptide 1-25 of β -casein

Jean-Michel Pérès, Said Bouhallab, Christelle Petit, François Bureau, Jean-Louis Maubois, Pierre Arhan, Dominique Bouglé

► To cite this version:

Jean-Michel Pérès, Said Bouhallab, Christelle Petit, François Bureau, Jean-Louis Maubois, et al.. Improvement of zinc intestinal absorption and reduction of zinc/iron interaction using metal bound to the caseinophosphopeptide 1-25 of β -casein. *Reproduction Nutrition Development*, 1998, 38 (4), pp.465-472. hal-00900222

HAL Id: hal-00900222

<https://hal.science/hal-00900222>

Submitted on 11 May 2020

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Original article

Improvement of zinc intestinal absorption and reduction of zinc/iron interaction using metal bound to the caseinophosphopeptide 1-25 of β -casein

Jean-Michel Pérès^a, Saïd Bouhallab^b, Christelle Petit^a,
François Bureau^c, Jean-Louis Maubois^b, Pierre Arhan^a,
Dominique Bouglé^{a, d*}

^a Laboratoire de physiologie digestive et nutritionnelle, CHU de Caen, 14033 Caen, France

^b Laboratoire de recherches de technologie laitière, Inra, 35042 Rennes, France

^c Laboratoire de biochimie A, CHU de Caen, 14033 Caen, France

^d Service de pédiatrie A, CHU de Caen, 14033 Caen, France

(Received 6 March 1998; accepted 28 May 1998)

Abstract – Binding zinc (Zn) to soluble caseinophosphopeptides (CN), produced by the hydrolysis of caseins, improves its absorption and could prevent inhibition by other nutrients such as iron (Fe). The absorption of Zn (100 μ mol/L) bound to the 1-25 CN (β -CN(1-25)) of β -casein, or as ZnSO₄ was studied using the isolated, perfused rat intestinal loop system. Fe (Fe–CN or Fe gluconate (Fe Gluc)) was added at Zn/Fe ratios of 2:1, 1:5 and 1:10. Disappearance from the lumen (Q1) and net absorption (ZnAbs) of Zn–CN were statistically greater than for ZnSO₄; Zn retention by the mucosa (Q2) did not significantly differ. Fe Gluc reduced Q1, Q2 and ZnAbs for ZnSO₄ at ratios of 1:5 and 1:10 and for Zn–CN at a ratio of 1:10. Fe–CN reduced Q1 and ZnAbs of both forms of Zn at a ratio of 1:10; Q2 remained unchanged. Binding Zn to β -CN(1-25) improved Zn absorption and prevented Fe from inhibiting its absorption. © Inra/Elsevier, Paris

zinc / iron / digestive absorption / caseinophosphopeptide / rat

Résumé – Augmentation de l'absorption intestinale du zinc et diminution des interactions zinc/fer en utilisant un métal lié au caséinophosphopeptide 1-25 de la β -caséine. La fixation du zinc (Zn) à des caséinophosphopeptides solubles (CN) produits par l'hydrolyse enzymatique des caséines pourrait augmenter son absorption et limiter l'inhibition exercée par d'autres nutriments tel le fer (Fe). L'absorption du Zn sous forme liée au 1-25 CN (β -CN(1-25)) de la β -caséine ou de ZnSO₄ a été étudiée par la méthode de l'intestin de rat isolé, perfusé. Le Fe (Fe–CN ou Gluconate (Fe Gluc)) a été ajouté à des rapports Zn/Fe de 2:1, 1:5 et 1:10 Zn/Fe. La disparition du Zn–CN de la lumière intestinale (Q1) et son absorption nette (ZnAbs) étaient significativement plus fortes que celles du ZnSO₄; la rétention muqueuse du Zn (Q2) ne diffère pas significativement entre les deux

* Correspondence and reprints

séries. Fe Gluc a diminué Q1, Q2 et ZnAbs de ZnSO₄ aux rapports 1:5 et 1:10, ne diminuant que Q1 et ZnAbs pour Zn-CN au rapport 1:10. Fe-CN a diminué Q1 et ZnAbs, au rapport 1:10 pour les deux formes de Zn. La fixation du Zn au β -CN (1-25) augmente son absorption et assure sa protection contre l'interaction inhibitrice du Fe. Les mécanismes en cause pourraient impliquer une augmentation de la solubilité intraluminal du Zn et l'étape de transfert entérocytaire. © Inra/Elsevier, Paris

zinc / fer / absorption digestive / caséinophosphopeptide / rat

1. INTRODUCTION

Zinc (Zn) is the cofactor of several hundred metalloenzymes involved in protein and nucleic acid synthesis [27]. Zn deficiency leads to anorexia [30], and affects tissues capable of rapid proliferation. A lack of Zn during critical prenatal and postnatal periods therefore impairs growth, bone and cerebral development [26, 30], gastro-intestinal tract function and immunity. However, Zn deficiency can also be an isolated cause of reduced growth rate [32].

Zn is mainly absorbed in the jejunum [1, 18]. Absorption depends on the dietary form of the Zn and on the presence of certain intraluminal factors. Thus, lactose and citric acid [23, 29] facilitate Zn uptake by the enterocyte, whereas phytates decrease Zn absorption [22]. Iron (Fe) inhibits Zn uptake and metabolism and Zn has a similar effect on Fe absorption [3, 11, 13, 17, 31].

Binding Zn to ligands such as dietary proteins can keep it soluble and enhance its intestinal absorption. The hydrolysis of caseins yields caseinophosphopeptides (CN) which bind calcium via their phosphoserine residues [2, 33]. Other divalent cations, such as Zn and Fe, can bind to phosphoserine residues in proportion to their degree of phosphorylation and according to the cation [4, 9, 33]. These CN are normally found in the intestinal lumen during digestion [20, 21]. They are somewhat resistant to digestive enzymes [4, 5, 28]. In vivo studies on the influence of CN on mineral absorption have given conflicting results. CN improve calcium absorption in rats by preventing the precipitation of calcium salts in the small

intestine [28, 35] but have no effect in the pig [24]. Other studies have shown them to have a limited effect on calcium absorption in the rat ileum [19]. β -CN (1-25) is produced by the hydrolysis of β -casein, and has four of the five phosphoserine residues of the native protein. Thus 1 mole can bind 4 moles of Fe or Zn with a greater affinity than for calcium [4]. Our previous studies showed that binding Fe to β -CN (1-25) increased its net absorption by normal and Fe deficient rats and decreased the inhibitory effect of calcium on Fe absorption [25]. The addition of CN to a solution containing phytates also increases the absorption of calcium and Zn in rat pups [14] and in adult humans [15].

The present study was performed to confirm in vivo the improved absorption of Zn in the presence of β -CN (1-25) and to assess the influence of β -CN (1-25) on the inhibition of Zn absorption by Fe. The absorption of Zn bound to purified β -CN (1-25) was compared to that of Zn sulfate using the isolated jejunal rat loop model. The inhibition of Zn absorption by Fe was studied using different concentrations of Fe as β -CN (1-25) bound Fe or Fe gluconate.

2. MATERIALS AND METHODS

2.1. Preparation of the 1-25 caseinophosphopeptide of β -casein (β -CN (1-25))

β casein (β -CN) was isolated from industrially produced sodium caseinate (Armor Protéines, Saint-Brice-en-Coglès, France) by cold solubilization (pH 4.5; 4 °C), followed by ion exchange

chromatography [2, 4]. β -CN (1-25) was obtained by tryptic digestion of β -casein. Fe and Zn were bound to β -CN (1-25) by adding FeCl_2 and ZnCl_2 to the solution (pH = 5.3; 30 min; 25 °C (Milli Q system, Millipore)). Unbound Fe and Zn were removed by ultracentrifugation and filtration through a regenerated cellulose membrane with a 3 000-Da cut-off (membrane SIOY3, Amicon, Lexington, MY). The resulting complex was freeze-dried. Complexed Fe and Zn and residual calcium were measured by atomic absorption spectrometry (Varian AA 1275). One mole of peptide bound 4 moles of Fe or Zn. A control without β -CN (1-25) was incubated and dialysed under the same conditions, to be sure that the variations of Zn and Fe concentrations were actually induced by binding to the phosphopeptide.

2.2. Animals

Adult female Sprague-Dawley rats weighing 250–300 g were starved for 12 h before study but had free access to water. The rats were assigned to 14 groups (six animals/group): rats were perfused with 100 $\mu\text{mol/L}$ Zn sulfate (ZnSO_4), or Zn bound to β -CN (1-25) (Zn-CN) alone or in the presence of Fe gluconate (Fe Gluc) (which remained soluble above pH = 4), or Fe bound to β -CN (1-25) (Fe-CN). The Fe concentrations were 50 $\mu\text{mol/L}$, 500 $\mu\text{mol/L}$, 1 000 $\mu\text{mol/L}$ giving Zn/Fe ratios of 2:1, 1:5 and 1:10. The absence of Zn adsorption to the digestive mucosa, which could have falsely improved the absorption rate, was checked by perfusing a group of dead rats. Another group of rats was perfused with a Zn-free solution to confirm that no significant Zn secretion occurred during the experiment.

2.3. Perfusion

The perfusion solute was adapted from Ringer-Lavoisier solute and was checked to be free of Zn contamination. Its pH was adjusted to that of the proximal jejunum pH (pH = 7); it was isotonic to plasma (285–300 mosmol) and contained 100 $\mu\text{mol/L}$ Zn as sulfate or Zn-CN. Rats were anesthetized with Ketamine (Ketalar™), which has no effect on gut motility. The erythrocytes were counted to prevent from anaemia which could disturb Fe absorption. Then the jejunum was exposed by a laparotomy. The loop was perfused through a catheter inserted at the angle of

Treitz; effluent was collected 5 cm lower. Solid material was washed out with 1 g/L Triton X100 in water to prevent any contamination. The perfusion solute was kept at 37 °C and was delivered at 0.16 mL/min for 2 h using a peristaltic pump to avoid loop distension; a non-absorbable marker (polyethylene glycol 4 000) was added to assess net water fluxes. The rat was killed with an overdose of Doléthal™, the perfused loop was washed with saline, withdrawn and dried in an oven at 90 °C to constant weight.

2.4. Assays

Zn and Fe concentrations in perfusion solute, gut effluent and the mucosa of the perfused segment were measured by atomic absorption (Perkin Elmer 3030); tissue was digested in 10 N nitric acid at ambient temperature for 24 h. Ringer-Lavoisier solute was used as blank.

Polyethyleneglycol (PEG) in the perfusion solute and the gut effluent was measured by a turbidimetric method [16].

The disappearance of Zn from the gut lumen (Q1: μmol) was calculated from:

$$Q1 = (1 - ([\text{PEG}]t / [\text{PEG}]e)) * ([\text{Zn}]e / [\text{Zn}]t)^* D * T * [\text{Zn}]t$$

where [PEG] and [Zn] were the PEG and Zn concentrations in the perfusion solute (t) and in the effluent (e). D and T are the delivery rate (mL/min) and the time of collection.

The Zn stored by the mucosa (Q2: μmol) during perfusion was calculated from:

$$Q2 = ([\text{Zn}]m - [\text{Zn}]m0) * Pm$$

where [Zn]m is the Zn concentration of perfused intestinal mucosa segment and Pm its weight; [Zn]m0 the Zn concentration of intestinal mucosa segment perfused with a Zn-free solute.

Net Zn absorption (Zn abs: μmol) during the perfusion was:

$$\text{Zn abs} = Q1 - Q2.$$

2.5. Statistics

Results are expressed as means and standard deviations. Groups were compared by two-way ANOVA followed by Student's *t*-test using 'Statview SE + Graphics™' within each group

(ZnSO₄ or Zn-CN). The effect of Fe is expressed as a ratio of the mean for the control Fe-free group (%). These values were also compared by ANOVA and Student's *t*-test. Significance was set at *P* < 0.05.

3. RESULTS

3.1. Absorption of ZnSO₄ and Zn-CN

Fe-free Zn absorptions are given in the first lines of *tables I* and *II*.

No significative change in Zn concentration in the perfusion solute was observed (100.12 μM before and after experience) while perfusing dead rats with ZnSO₄: Zn disappearance from gut lumen was only due to Zn uptake by enterocytes and not to Zn adsorption to the digestive mucosa.

Zn-CN was lost from the intestinal lumen (Q1) significantly faster than ZnSO₄. Zn

retention by the mucosa (Q2) of the two groups was essentially the same. The net absorption (ZnAbs) of Zn-CN was statistically greater than that of ZnSO₄.

3.2. Effect of different forms of Fe on ZnAbs

The influence of different forms of Fe on ZnSO₄ and Zn-CN absorption are shown in *tables I* and *II*. Low concentrations of Fe Gluc (Zn/Fe ratio: 2:1) significantly reduced Q1 and ZnAbs of ZnSO₄ (*table I*). Higher concentrations of Fe Gluc (Zn/Fe ratio: 1:5; 1:10) inhibited these two parameters and Q2. Inhibition was significantly greater at a Zn/Fe ratio of 1:10.

Fe-CN reduced significantly Q1 and ZnAbs at a Zn/Fe ratio of 1:10. The influence of the form of Fe on Zn absorption

Table I. Effect of iron on zinc sulfate absorption

| | % Q1 | % Q2 | % ZnAbs Anova |
|------------------------------|---|--|---|
| 1 ZnSO ₄ | 27.629 ± 0.003 <i>P</i> < 0.001 | 7.579 ± 0.001 | 20.050 ± 0.003 |
| 2 Fe Gluc (50 μM) | 27.383 ± 0.003 <i>P</i> < 0.001 | 7.568 ± 0.001 | 19.815 ± 0.004 |
| 3 Fe Gluc (500 μM) | 23.042 ± 0.001 ^{a,b} <i>P</i> < 0.001 | 5.451 ± 0.001 ^{a,b} | 17.591 ± 0.002 ^{a,b} |
| 4 Fe Gluc (1000 μM) ANOVA | 22.160 ± 0.002 ^{a,b,c} <i>P</i> < 0.001 | 5.195 ± 0.001 ^{a,b,c} <i>P</i> < 0.001 | 16.966 ± 0.002 ^{a,b,c} <i>P</i> < 0.001 |
| 5 FeCN (50 μM) | 27.299 ± 0.001 <i>P</i> < 0.001 | 7.353 ± 0.002 | 19.946 ± 0.001 |
| 6 FeCN (500 μM) | 27.374 ± 0.003* <i>P</i> < 0.001 | 7.574 ± 0.002* | 19.820 ± 0.005* |
| 7 FeCN (1000 μM) ANOVA | 26.978 ± 0.002 ^{a,d,*} <i>P</i> < 0.001 | 7.523 ± 0.003* NS | 19.455 ± 0.005 ^{a,d,*} <i>P</i> < 0.05 |

Results are expressed as a ratio to the total amount of perfused Zn (%); mean ± 1 SD.

Rats were perfused with perfusion solute containing Zn sulfate (100 μmol/L); Fe gluconate (Fe Gluc) or Fe bound to β-CN (1-25) (Fe-CN) was added at different concentrations. Q1: Zn lost from gut lumen; Q2: Zn stored by the mucosa; ZnAbs: absorbed Zn; ^a Different (*P* < 0.001) from control group ZnSO₄ (1); ^b different (*P* < 0.001) from (2); ^c different (*P* < 0.001) from (3); ^d different (*P* < 0.001) from (5); * different (*P* < 0.001) from group perfused with a different form of Fe but same concentration of Fe.

was assessed by comparing groups perfused with the same Fe concentrations and the same form of Zn. Q1, Q2 and ZnAbs were significantly different when Fe was present as Fe Gluc and as Fe–CN at Zn/Fe ratios of 1:5 and 1:10.

Table II shows that low concentrations (2:1 ratio) of Fe Gluc did not reduce Q1, Q2 and ZnAbs for Zn–CN. Higher concentrations of Fe Gluc (Zn/Fe ratio: 1:5 and 1:10) reduced Q1 and ZnAbs; this inhibition was significantly greater when the ratio was 1:10.

Fe–CN at the ratio of 1:10 significantly inhibited Q1 and ZnAbs. Perfusion with the same concentrations of Fe Gluc or Fe–CN had significantly different effects on Q1 and ZnAbs when the ratio was 1:10.

Figure 1 shows the results expressed as the inhibition of absorption of the two forms of Zn by the two forms of Fe. This inhibition was significantly greater while perfusing ZnSO₄ with low Zn/Fe ratios (1:5 and 1:10), but was similarly weak when Zn (as ZnSO₄

or Zn–CN) was perfused with Fe Gluc (at 2:1 ratio) or Fe–CN (at any ratio). This inhibition became statistically lower in rats perfused with Zn–CN than in rats perfused with ZnSO₄ at low Zn/Fe ratios (1:5 and 1:10).

4. DISCUSSION

Zn absorption in the jejunum [18] is influenced by Zn status [27], owing to the synthesis of metallothionein, a cysteine-rich protein [8]. But it is passive and linearly proportional to the luminal concentration of Zn between 0.1 mol/L and 1.8 mol/L [18]. Thus Zn absorption is influenced by the form of dietary Zn [31] and by interactions with substances in the gut which enhance absorption, such as proteins and glucose polymers [27, 29], or inhibit it such as phytates or other trace elements (Fe) which compete for common carriers [7].

Although caseinophosphopeptides (CN) positively influence Fe absorption [25], they

Table II. Effect of iron on absorption of zinc bound to β -CN (1-25)

| | % Q1 | % Q2 | % ZnAbs |
|---------------------------|-------------------------------------|-------------------|-------------------------------------|
| 8 Zn–CN | 37.395 \pm 0.008 | 7.365 \pm 0.002 | 30.030 \pm 0.008 |
| 9 Fe Gluc (50 μ M) | 37.041 \pm 0.001 | 7.339 \pm 0.001 | 29.702 \pm 0.001 |
| 10 Fe Gluc (500 μ M) | 36.263 \pm 0.002 ^{a,b} | 7.352 \pm 0.004 | 28.911 \pm 0.003 ^{a,b} |
| 11 Fe Gluc (1000 μ M) | 35.180 \pm 0.002 ^{a,b,c} | 7.134 \pm 0.003 | 28.046 \pm 0.004 ^{a,b,c} |
| ANOVA | <i>P</i> < 0.001 | NS | <i>P</i> < 0.001 |
| 12 Fe–CN (50 μ M) | 37.041 \pm 0.004 | 7.277 \pm 0.002 | 29.764 \pm 0.005 |
| 13 Fe–CN (500 μ M) | 36.618 \pm 0.003 | 7.310 \pm 0.004 | 29.308 \pm 0.005 |
| 14 Fe–CN (1 000 μ M) | 36.161 \pm 0.005 ^{a,d*} | 7.277 \pm 0.003 | 28.885 \pm 0.007 ^{a,d*} |
| ANOVA | <i>P</i> < 0.001 | NS | <i>P</i> < 0.05 |

Results are expressed as a ratio to the total amount of perfused Zn (%); mean \pm 1 SD.

Rats were perfused with perfusion solute containing Zn bound to β -CN (1-25) (100 μ mol/L). Iron was added as Fe gluconate (Fe Gluc) or bound to β -CN (1-25) (Fe–CN). Q1: Zn lost from gut lumen; Q2: Zn stored by the mucosa; ZnAbs: absorbed Zn; ^a Different (*P* < 0.001) from control group Zn–CN (8); ^b different (*P* < 0.001) from (9); ^c different (*P* < 0.001) from (10); ^d different (*P* < 0.001) from (12); * different (*P* < 0.001) from group perfused with a different form of Fe but with same concentration of Fe.




Figure 1. Inhibition of zinc absorption by different forms of iron. Results are expressed as the ratio to the mean value of the iron free group (%). 100 µmol/L Zinc (ZnSO₄ or Zn-CN) was perfused in the presence of 50, 500, 1 000 µmol/L iron (Fe Gluc or Fe-CN). Q1: Zn lost from the gut lumen; Q2: Zn stored by the mucosa; ZnAbs: absorbed Zn. Significance of the difference versus control: * *P* < 0.001; ** *P* < 0.05.

have given conflicting results on Zn absorption [14, 15]. The present *in vivo* study confirms that Zn bound to β -CN(1-25) is absorbed better than the widely used inorganic salt ZnSO_4 . This effect appears to be greater than previously reported [14]. We used a well-defined purified CN from β -casein (β -CN (1-25)) to which Zn was bound and not just added [14]. The adult rats used in our work also differ from the rat pups and humans [14, 15].

Our results also support our previous findings on the protection against inhibition offered by binding trace elements to β -CN (1-25) [25]. This occurs when one of the trace elements is provided in a bound form, and is enhanced when both are bound. Only the higher Zn/Fe ratio (2:1) showed no inhibition of Zn absorption by Fe in whatever form. Zn absorption can be inhibited by Fe with Zn/Fe ratios below one-half in dietary or fortification forms of trace elements [10, 29], as shown in the present study. However, although Zn absorption was inhibited by Fe Gluc for both forms of Zn at a ratio of 1:5, the absorption of bound Zn remained 60 % higher than that of ZnSO_4 ; Zn absorption was not inhibited by Fe when both trace elements were provided in a bound form at this ratio.

This enhanced Zn absorption could be due to the Zn bound to soluble β -CN (1-25) being protected from insolubilization during digestion [2], or from interactions with other food in the gut, such as phytates [14]. β -CN (1-25) could also influence Zn absorption by the enterocytes, particularly during apical membrane uptake, where inhibitory interactions between trace elements can occur [34]. Fe and Zn could compete for a common metal-ion transporter [12] and carrier proteins involved in trace element transport from membrane receptor into the enterocyte [7]. Changes in the storage of Zn by enterocytes according to the form of perfused Fe support this assumption. Zn binding to β -CN (1-25) could be resistant to hydrolysis at low pH and by digestive enzymes,

but this remains to be demonstrated; Zn could be absorbed by some mechanism other than passive or carrier-mediated uptake. Zn and Fe bound to β -CN (1-25) could be taken up by endocytosis while chelated to a peptide or an amino acid, as reported for dietary peptides and proteins [6].

CONCLUSION

Zn bound to β -CN (1-25) is absorbed better than Zn sulfate. Its absorption is protected from inhibition by Fe. The mechanisms involved remain to be identified. Further studies are needed to validate these results in man, before this bound form of Zn could be proposed as a food additive.

REFERENCES

- [1] Andersen O., Nielsen J.B., Sorensen J.A., Scherbeck L., Experimental localization of intestinal uptake sites for metals (Cd, Hg, Zn, Se) in *in vivo* in mice, *Env. Health Perspect.* 102 (1994) 199–206.
- [2] Baomy J.J., Brulé G., Effect of pH and ionic strength on the binding of bivalent cations to β -casein, *Lait* 68 (1988) 90–101.
- [3] Bouglé D., Isfaoun A., Bureau F., Neuville D., Jauzac P., Arhan P., Long term effects of Fe: Zn interactions on growth in rats, *Biol. Trace Elem. Res.* (1998) in press.
- [4] Bouhallab S., Leonil J., Maubois J.L., Complexation du fer par le phosphopeptide (1-25) de la caséine β : action de l'alcalase et de la phosphatase acide, *Lait* 71 (1991) 435–443.
- [5] Brommage R., Juillerat M.A., Jost R., Influence of casein phosphopeptides and lactulose on intestinal calcium absorption in adult female rats, *Lait* 71 (1991) 173–180.
- [6] Caillard I., Tomé D., Transport des antigènes protéiques majeurs du lactosérum bovin dans l'épithélium intestinal, *Cah. Nutr. Diet.* 30 (1995) 306–312.
- [7] Conrad M.E., Regulation of Fe absorption, *Prog. Clin. Biol. Res.* 380 (1993) 203–219.
- [8] Cousins R.J., Smith K.T., Zn-binding properties of bovine and human milk *in vitro*: influence of changes in Zn content, *Am. J. Clin. Nutr.* 33 (1979) 1083–1087.
- [9] Demott B.J., Dincer B., Binding added Fe to various milk proteins, *J. Dairy Sci.* 59 (1976) 1557–1559.

- [10] Fairweather-Tait S.J., Southon S., Studies of Fe: Zn interactions in adult rats and the effect of Fe fortification of two commercial infant weaning products on Fe and Zn status of weanling rats, *J. Nutr.* 119 (1989) 599–606.
- [11] Gòmez-Ayala A.E., Campos M.S., Lòpez-Aliaga I., Pallàres I., Hartiti S., Barrionevo M., Alfèrez M.J.M., Ròdriguez-Matas M.C., Lisbona F., Effect of source of Fe on duodenal absorption of Fe, calcium, phosphorus, magnesium, copper and Zn in rats with ferropeenic anaemia, *Int. J. Vit. Nutr. Res.* 67 (1997) 106–114.
- [12] Gunshin H., MacKenzie B., Berger V., Gunshin Y., Romero M.F., Boron W.F., Nussberger S., Gollan J.L., Hediger M.H., Cloning characterization of mammalian proton-coupled metal-ion transporter, *Nature* 388 (1997) 482–488.
- [13] Hamilton D.L., Bellamy J.E.C., Valberg J.D., Valberg L.S., Zn, Cadmium and Fe interactions during intestinal absorption in Fe-deficient mice, *Can. J. Physiol. Pharmacol.* 56 (1978) 384–389.
- [14] Hansen M., Sandström B., Lonnerdal B., The effect of casein phosphopeptides on Zn and calcium absorption from high phytate infant diets assessed in rats pups and CaCo-2 cells, *Pediatr. Res.* 40 (1996) 547–552.
- [15] Hansen M., Sandström B., Jensen M., Sorensen S.S., Casein phosphopeptides improve Zn and calcium absorption from rice-based but not from whole-grain infant cereal, *J. Pediatr. Gastroenterol. Nutr.* 24 (1997) 56–62.
- [16] Hyden S., A turbidometric method for determination of higher polyethylene glycols in biological materials, *Ann. R. Agr. Coll. Sweden* 22 (1955) 139–145.
- [17] Isfaoun A., Bureau F., Mouly-Boudey M., Drowsky M., Arhan P., Bouglé D., Relationships between Fe and Zn metabolism: predictive value of digestive absorption on Zn storage, *J. Tr. Elem. Electrol.* 14 (1997) 24–26.
- [18] Lee H.H., Prasad A.S., Brewer G.J., Owyang C., Zn absorption in human small intestine, *Am. J. Physiol.* 256 (1989) 516–519.
- [19] Li Y., Tomé D., Desjeux J.F., Indirect effect of casein phosphopeptides on calcium absorption in rats ileum *in vitro*, *Reprod. Nutr. Dev.* 29 (1989) 227–233.
- [20] Meisel H., Frister H., Chemical characterization of bioactive peptides from *in vivo* digests of casein, *J. Dairy Res.* 56 (1989) 343–349.
- [21] Naito H., Suzuki H., Further evidence for the formation *in vivo* of phosphopeptide in the intestinal lumen from dietary β -casein, *Agr. Biol. Chem.* 38 (1974) 1543–1545.
- [22] O'Dell B.L., Effect of dietary components upon Zn availability, *Am. J. Clin. Nutr.* 22 (1969) 1315–1322.
- [23] Pabon M.L., Lönnerdal B., Effect of citrate on Zn bioavailability from milk, milk fractions and infant formulas, *Nutr. Res.* 13 (1993) 103–111.
- [24] Pointillart A., Guéguen L., Absence d'effet de l'incorporation d'un phosphopeptide du lait ou l'utilisation du calcium et du phosphore chez le jeune porc, *Reprod. Nutr. Dev.* 29 (1989) 477–486.
- [25] Pérès J.M., Bouhallab S., Bureau F., Maubois J.L., Arhan P., Bouglé D., Absorption digestive du fer lié au caséinophosphopeptide 1-25 de la β -caséine, *Lait* 77 (1997) 433–440.
- [26] Sandström B., Zn absorption from composite meals. I. The influence of wheat extraction rate, Zn, calcium and protein content in meals based on bread, *Am. J. Clin. Nutr.* 33 (1980) 739–745.
- [27] Sandström B., Bioavailability of Zn, *Eur. J. Clin. Nutr.* 51 (1997) S17–S19.
- [28] Sato R., Noguchi T., Naito H., Casein phosphopeptide enhances calcium absorption from ligated segment of rat small intestine, *J. Nutr. Sci. Vitaminol.* 32 (1986) 67–76.
- [29] Solomons N.W., Biological availability of Zn in humans, *Am. J. Clin. Nutr.* 35 (1982) 1048–1075.
- [30] Taylor A., Measurement of Zn in clinical samples, *Ann. Clin. Biochem.* 34 (1997) 142–150.
- [31] Valberg L.S., Flanagan P.R., Chamberlain M.J., Effects of Fe, tin and copper on Zn absorption in humans, *Am. J. Clin. Nutr.* 40 (1984) 536–541.
- [32] Walravens P.A., Hambudge K.M., Growth of infants fed a Zn supplemented formula, *Am. J. Clin. Nutr.* 29 (1976) 1114–1121.
- [33] West D.W., Structure and function of the phosphorylated residues of casein, *J. Dairy Res.* 53 (1986) 333–352.
- [34] Wien E.M., Glahn R.P., Van Campen D.R., Ferrous Fe uptake by rat duodenal brush border membrane Vesicles: effects of dietary Fe level and competing minerals (Zn^{2+} , Mn^{2+} and Ca^{2+}), *J. Nutr. Biochem.* 5 (1994) 571–577.
- [35] Yuan Y.V., Kitts D.D., Confirmation of calcium absorption and femoral utilization in spontaneously hypertensive rats fed casein phosphopeptide supplemented diets, *Nutr. Res.* 11 (1991) 1257–1272.